Effects of racecadotril and loperamide on bacterial proliferation and on the central nervous system of the newborn gnotobiotic piglet

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 13, Issue 6, 1999, Pages 9-14

  Duval Iflah, Y ^a   Berard, H ^b   Baumer, P ^b   Guillaume, P ^a   Raibaud, P ^a   Joulin, Y ^b   Lecomte, J M ^b  

^a CEMAGREF   (France)

^b Bioprojet   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETORPHAN; ANTIDIARRHEAL AGENT; ENKEPHALINASE INHIBITOR; LOPERAMIDE; MU OPIATE RECEPTOR AGONIST; STOMACH SECRETION INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GROWTH; BACTERIAL OVERGROWTH; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEATH; DRUG EFFECT; DRUG TOLERABILITY; ESCHERICHIA COLI; GNOTOBIOTICS; INTESTINE FLORA; JEJUNUM; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 0010298406     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00001.x-i1     Document Type: Article

References (48)

1. 1 Baumer Ph, Danquechin-Dorval E, Bertrand J, Vetel JM, Schwartz JC, Lecomte JM. Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea. Gut 1992; 33: 753-8.
2. 2 Ruppin H. Review: loperamide, a potent antidiarrhoeal drug with actions along the alimentary tract. Aliment Pharmacol Ther 1987; 1: 179-90.
3. 3 Bergmann JF. Chaussade S, Couturier D, Baumer Ph, Schwartz JC, Lecomte JM. Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers. Aliment Pharmacol Ther 1992; 6: 305-13.
4. 4 Marçais-Collado H, Uchida G, Costentin J, Schwartz JC, Lecomte JM. Naloxone reversible antidiarrheal effect of enkephalinase inhibitors. Eur J Pharmacol 1987; 144: 125-32.
5. 5 Lecomte JM, Costentin J, Vlaiculescu A, et al. Pharmacological properties of acetorphan, a parenterally active 'enkephalinase inhibitor'. J Pharmacol Exp Ther 1986; 237: 937-44.
6. 6 Sninsky CA, Davis RH, Clench MH, Thomas KD, Mathias JR. Effect of lidamidine hydrochloride and loperamide on gastric emptying and transit of the small intestine. A double blind study. Gastroenterology 1986; 90: 68-73.
7. 7 Basilisco G, Bozzani A, Camboni G, et al. Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test. Gut 1985; 26: 700-3.
8. 8 Basilisco G, Camboni G, Bozzani A, Paravicini M, Bianchi PA. Oral naloxone antagonizes loperamide-induced delay of oro-caecal transit. Dig Dis Sci 1987; 32: 829-32.
9. 9 Heel RC, Brogden RN, Speight TM, Avery GS. Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 1978; 15: 33-52.
10. 10 Karaus M, Enck P, Erckenbrecht JF, Strohmeyer G. Loperamide and its prodrug, lopoxyde, have different effects on small and large bowel motility. Gastroenterology 1990; 98: A364 (Abstract).
11. 11 Kachel G, Ruppin H, Hagel J, Barma W, Meinhardt M, Domschke W. Human intestinal motor activity and transport: effects of a synthetic opiate. Gastroenterology 1986; 90: 85-93.
12. 12 Vantrappen G, Janssens J, Hellemans J. Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest 1977; 59: 1158-66.
13. 13 Hocking MP, Carlson RG, Courington KR, Bland KI. Altered motility and bacterial flora after functional end-to-end anastomosis. Surgery 1990; 108: 384-92.
14. 14 Edelman R. Prevention and treatment of infectious diarrhoea. Speculations on the next 10 years. Am J Med 1985; 78: 99-106.
15. 15 Editorial. Le risque du lopéramide (Imodium) chez l'enfant. Revue Prescrire 1991; 108: 293-4.
16. 16 Ducluzeau R, Raibaud P, Lauvergeon B, et al. Immediate post-natal decontamination as a mean of obtaining axenic animals and human infants. Can J Microbiol 1976; 22: 563-6.
17. 17 Duval-Iflah Y, Chappuis JP. Entéropathogénicité de différentes souches de Escherichia coli chez le porcelet gnotoxénique. La diarrhée du jeune. Les Colloques de l'Inserm 1984; 121: 167-76.
18. 18 Chappuis JP, Duval-Iflah Y, Ollivier L, Legault C. L'attachement de Escherichia coli K88: comparaison entre porcelets Chinois et Large White. Génét Sél Evol 1984; 16: 385-90.
19. 19 Chappuis JP, Duval-Iflah Y, Ducluzeau R, Raibaud P. Resistance of gnotobiotic Large White and Chinese piglets to in vivo attachment of a K88ab enterotoxigenic Escherichia coli strain. Reprod Nutr Dévelop 1985; 25: 49-60.
20. 20 Duval-Iflah Y, Chappuis JP, Ducluzeau R, Raibaud P. Intraspecific interactions between Escherichia coli strains in human newborns and in gnotobiotic mice and piglets. Prog Fd Nutr Sci 1983; 7: 107-16.
21. 21 Duval-Iflah Y, Ollivier L, Guérin G, Bonneau M, Caritez JC, Renard C. La colibacillose néo-natale K88 du porc. Résultats génétiques préliminaires. Ann Rech Vét 1987; 18: 333-4.
22. 22 Runkel NSF, Moody FG, Smith GS, et al. Alterations in rat intestinal transit by morphine promote bacterial translocation. Dig Dis Sci 1993; 38: 1530-6.
23. 23 Schiller LR, Santa Ana CA, Morawski SG, Fordtran JS. Mechanism of the antidiarrhoeal effect of loperamide. Gastroenterology 1984; 86: 1475-80.
24. 24 Schuermans V, Vancommel R, Don Brugmans J. Loperamide (R 18, 553) a novel type of antidiarrhoeal agent. Placebo-controlled comparison of the constipating activity and safety of loperamide, diphenoxylate and codeine in normal volunteers. Arzneimittelforschung (Drug Res) 1974; 24: 1653-7.
25. 25 Rogé J. Baumer Ph, Bérard H, Schwartz JC, Lecomte JM. The enkephalinase inhibitor, acetorphan, in acute diarrhea: a double-blind controlled clinical trial versus loperamide. Scand J Gastroenterol 1993; 28: 352-4.
26. 26 Nieuwenhuijs VB, Verheem A, Beumer H, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth and bacterial translocalion in rats. Gastroenterology 1997; 112: A798 (Abstract).
27. 27 Chow CB, Li SH, Leung NK. Loperamide associated necrotising enlerocolitis. Acta Paediatr Scand 1986; 75: 1034-6.
28. 28 Olm M, Gonzalez FJ. Garcia-Valdecasas JC, Fuster J, Bertran A, Milla J. Necrotising colitis with perforation in diarrhoea patients treated with loperamide. Eur J Clin Pharmacol 1991; 40: 415-6.
29. 29 Smith FW, Law DH, Nickel WF Jr. Sleisenger MH. Fulminant ulcerative colitis with toxic dilation of the colon: medical and surgical management of eleven cases with observations regarding etiology. Gastroenterology 1962; 42: 233-43.
30. 30 McInerney GT, Sauer WG, Baggenstoss AH, Hodgson JR. Fulminating ulcerative colitis with marked colonic dilation; a clinicopathologic study. Gastroenterology 1962; 42: 244-7.
31. 31 Kirsner JB. Toxic megacolon complicating ulcerative colitis: current therapeutic perspectives. Gastroenterology 1974; 66: 1088-90.
32. 32 Brown JW. Toxic megacolon associated with loperamide therapy. JAMA 1979; 241: 501-2.
33. 33 Garrett JM, Sauer WG, Moertel CG. Colonic motility in ulcerative colitis after opiate administration. Gastroenterology 1967; 53: 93-100.
34. 34 Walley T, Milson D. Loperamide related toxic megacolon in Clostridium difficile colitis. Postgrad Med J 1990; 66: 582-4.
35. 35 Galambos JT. Loperamide, a new antidiarrhoeal agent in the treatment of chronic diarrhoea. Schweiz Med Wochenschr 1978; 108: 1080-1.
36. 36 Cimolai N, Carter JE, Morrison BJ. Andersen JD. Risk factors for the progression of Escherichia coli 0157; H7 enteritis to hemolytic-uremic syndrome. J Pediatr 1990; 116: 589-92.
37. 37 DuPont HL, Hornick HB. Adverse effect of Lomotil therapy in shigellosis. JAMA 1973; 226: 1525-8.
38. 38 Sprinz H. Palhogenesis of intestinal infections. Arch Pathol 1969; 87: 556-62.
39. 39 Pittman FE. Adverse effects of lomotil. Gastroenterology 1974; 67: 408-9.
40. 40 Toskes Ph, Donaldson RM Jr. The blind loop syndrome in gastrointestinal disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease, Pathophysiology, Diagnosis, Management. Philadelphia: W.B. Saunders, 1989: 1289-97.
41. 41 Dooley CP, El Newihi HM, Zeidler A, Valenzuela JE. Abnormalities of the migrating motor complex in diabetics with autonomic neuropathy and diarrhoea. Scand J Gastroenterol 1988; 23: 217-23.
42. 42 Haboubi NY, Montgomery RD. Small-bowel bacterial over-growth in elderly people: clinical significance and response to treatment. Age Ageing 1992; 21: 13-9.
43. 43 O'Boyle CJ. Murchan P, Mitchell CJ, Macfie J. Bacterial translocation is associated with upper gastrointestinal colonization in surgical patients. Gut 1996; 38: 40A.
44. 44 Physicians' desk reference. 52nd edn New Jersey: Medical Economics Company, 1998: 1304, 1540.
45. 45 Spillantini MG, Geppetti P, Fanciullacci M, Michelacci S, Lecomte JM, Sicuteri F. In vivo 'enkephalinase' inhibition by acetorphan in human plasma and CSF. Eur J Pharmacol 1986; 125: 147-50.
46. 46 Knisely JS. Beardsley PM, Aceto MD, Balster RL, Harris LS. Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor. Drug Alcohol Depend 1989; 23: 143-51.
47. 47 Turck D, Bérard H, Frétault N, Lecomte JM. Comparison of racecadotril and loperamide in children with acute diarrhoea. Aliment Pharmacol Ther 1999; 13(SuppI. 6): 27-32.
48. 48 Cézard JP, Duhamel JF, Meyer M, et al. Efficacy and tolerance of acetorphan in infant acute diarrhoea. A multicentric double blind study. Gastroenterology 1996; 110: 795A (Abstract).